Seelos Therapeutics Inc (SEEL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Raj Mehra Ph.D.
Employees:
7
300 Park Avenue, 12th Floor, New York, NY 10022
646-998-6475

Seelos Therapeutics, Inc. is a clinical-stage bio-pharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and in rare diseases. The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos Therapeutics was founded in 2016 and is based in New York, New York. Seelos’ common stock is traded on The Nasdaq Capital Market under the symbol "SEEL"

Data derived from most recent annual or quarterly report
Market Cap 59.506 Million Shares Outstanding105.507 Million Avg 30-day Volume 1.215 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.42
Price to Revenue0.0 Debt to Equity0.0636 EBITDA-18.832 Million
Price to Book Value0.4626 Operating Margin0.0 Enterprise Value64.793 Million
Current Ratio2.355 EPS Growth0.829 Quick Ratio2.108
1 Yr BETA 1.7408 52-week High/Low 5.24 / 0.48 Profit Margin0.0
Operating Cash Flow Growth22.0905 Altman Z-Score5.9688 Free Cash Flow to Firm -20.033 Million
Earnings Report2022-08-05
View SEC Filings from SEEL instead.

View recent insider trading info

Funds Holding SEEL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SEEL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

66.7 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MEHRA RAJ SEE REMARKS

  • Officer
  • Director
3,281,546 2022-03-31 2

GOLEMBIEWSKI MICHAEL JOSEPH CHIEF FINANCIAL OFFICER

  • Officer
78,487 2022-02-28 3

DALESANDRO MARGARET

  • Director
35,000 2022-01-05 3

PASCOE RICHARD W

  • Director
35,000 2022-01-05 1

O'CONNOR DANIEL J.

  • Director
35,000 2022-01-05 1

LIAN BRIAN

  • Director
35,000 2022-01-05 1

DUNN JUDITH

  • Director
0 2021-01-06 0

SMITH ROBIN L

  • Director
0 2020-01-06 0

MORTON NEIL SVP, CHIEF BUSINESS OFFICER

  • Officer
100,158 2019-01-23 0

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • 10% Owner
13,800,000 2018-09-20 0

DORSEY BRIAN

  • FORMER SVP, CHIEF DEV OFFICER
No longer subject to file 2018-08-30 0

DENNER ALEXANDER J

SARISSA CAPITAL MANAGEMENT LP

SARISSA CAPITAL OFFSHORE MASTER FUND LP

  • 10% Owner
0 2018-03-21 0

MAIER PAUL V

  • Director
0 2018-01-04 0

WIERENGA WENDALL

  • Director
0 2018-01-04 0

SMITH SANDFORD D

  • Director
0 2018-01-04 0

XANTHOPOULOS KLEANTHIS G

  • Director
0 2018-01-04 0

RAY RUSTY

  • Director
0 2018-01-04 0

DENNER ALEXANDER J

SARISSA CAPITAL MANAGEMENT LP

SARISSA CAPITAL DOMESTIC FUND LP

SARISSA CAPITAL OFFSHORE MASTER FUND LP

  • 10% Owner
2,120,359 2017-08-31 0

BOVENIZER CATHERINE VP FINANCE & CAO

  • Officer
34,594 2016-05-20 0

TROUPIN BARBARA SVP, CHIEF MEDICAL OFFICER

  • Officer
43,918 2016-03-15 0

GILLESPIE DEIRDRE

  • Director
0 2016-01-04 0

DENNER ALEXANDER J

SARISSA CAPITAL MANAGEMENT LP

SARISSA CAPITAL DOMESTIC FUND LP

  • 10% Owner
6,524,505 2015-02-13 0

MARTIN STEVEN ROBERT SENIOR VP & CFO

  • Officer
0 2014-02-20 0

COX EDWARD M. VP OF BUSINESS DEVELOPMENT

  • Officer
0 2014-02-20 0

OPPENHEIM LEONARD A

  • Director
0 2014-02-06 0

BERHOLTZ RANDY E.V.P., GENERAL COUNSEL & SEC.

  • Officer
0 2012-12-18 0

DAMAJ BASSAM PRESIDENT AND CEO

  • Officer
  • Director
3,222,734 2012-08-21 0

ESBER HENRY JEMIL

  • Director
609,217 2012-01-03 0

CREA ROBERTO

  • Director
27,551 2011-01-05 0

LIU VIVIAN H EXECUTIVE VICE PRESIDENT

  • Officer
  • Director
No longer subject to file 2010-12-31 0

BERMAN RICHARD J

  • Director
23,965 2010-06-30 0

WESTGATE MARK VICE PRESIDENT & CFO

  • Officer
879,318 2010-04-09 0

WADE MARTIN R III

  • Director
191,290 2009-10-06 0

EMIL ARTHUR D

  • Director
323,579 2009-10-06 0

TIERNEY DAVID S

  • Director
267,948 2009-10-06 0

PANDYA HEMANSHU

  • FORMER OFFICER
0 2009-08-27 0

MAY JACOB

  • OWNS MORE THAN 5% OF SECURITY
5,714,630 2009-07-07 0

SOUTHPOINT CAPITAL ADVISORS LP

SOUTHPOINT GP, LP

SOUTHPOINT CAPITAL ADVISORS LLC

SOUTHPOINT GP, LLC

BUTTS ROBERT W

CLARK JOHN SMITH II

  • 10% Owner
7,927,952 2008-05-12 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MEHRA RAJ - Director - Officer SEE REMARKS

2022-03-31 16:34:22 -0400 2022-03-31 P 66,667 $0.85 a 3,281,546 direct 5.2332 -4.8919 5.2332 2 -4.8919 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SEELOS THERAPEUTICS INC SEEL 2022-05-16 16:15:03 UTC -0.1562 0.9762 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 15:45:03 UTC -0.1562 0.9762 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 15:15:03 UTC -0.1562 0.9762 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 14:45:03 UTC -0.18 1.0 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 14:15:03 UTC -0.18 1.0 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 13:45:04 UTC -0.18 1.0 1600000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 13:15:03 UTC -0.18 1.0 1500000
SEELOS THERAPEUTICS INC SEEL 2022-05-16 12:45:04 UTC -0.18 1.0 1500000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 22:15:03 UTC -0.18 1.0 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 21:45:03 UTC -0.1737 0.9937 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 21:15:03 UTC -0.1737 0.9937 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 20:45:03 UTC -0.208 1.028 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 20:15:03 UTC -0.208 1.028 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 19:45:04 UTC -0.208 1.028 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 19:15:03 UTC -0.208 1.028 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 18:45:03 UTC -0.2006 1.0206 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 18:15:03 UTC -0.2006 1.0206 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 17:45:03 UTC -0.2006 1.0206 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 17:15:03 UTC -0.2006 1.0206 800000
SEELOS THERAPEUTICS INC SEEL 2022-05-13 16:45:03 UTC -0.1734 0.9934 800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments